Exfoliative Cytological Sample Collection Template

Excisional biopsy of oral tissue - hard.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Site: Site/tooth area
Lesion description: Lesion description
Size: Size
Duration: Duration

Consent: Consent/PARQ reviewed; signed/verbally obtained

Biopsy code support: Incisional/excisional/cell collection
Clinical appearance: Color, borders, ulceration, induration, symptoms
Pre-op photo/size/location: Photo taken; lesion size and anatomical location
Removal method/pathology: Method of tissue removal; lab sent; pathology result follow-up plan

Radiographs/images: Radiographs/images reviewed/taken and findings

Anesthesia: Anesthetic used
Carps: Carpules/amount

Procedure:
Entire lesion excised with margins.
Specimen includes margin of normal tissue.
Hemostasis achieved.
Sutured with: Suture material/size

Specimen placed in formalin.
Sent to pathology lab: Pathology lab/specimen details

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.

Results to be discussed at follow-up.

NV: Next visit

Documentation requirements

Whichever descriptor your payer is on, the documentation principle is the same: a third-party reviewer must be able to reconstruct the lesion, the technique, the specimen handling, and the follow-up plan from the chart note alone. For current-CDT D7287 (exfoliative cytology), the note should make the cell-collection nature of the procedure unmistakable.

• Medical history reviewed/updated — meds, anticoagulants (matters less for cytology than for incisional/excisional, but still document), allergies, immunosuppression, prior head/neck radiation, smoking/alcohol/HPV risk factors. Risk factors justify the workup.
• Vitals — BP and pulse at minimum on any in-office surgical or sampling encounter.
• Site / anatomic location — exact mucosal site (left lateral tongue, right buccal mucosa at occlusal plane, floor of mouth midline, etc.). Side and landmark, not just "tongue."
• Lesion description — color, border definition, surface texture (smooth, verrucous, granular, ulcerated), induration, fixation, symptoms (pain, paresthesia, bleeding). Objective findings, not conclusions.
• Size — measured in mm (length x width, depth/induration if assessable). "Small" is not a measurement.
• Duration — how long the lesion has been present per the patient and any change over time. Persistent >14 days raises the index of suspicion enough to justify sampling.
• Pre-op clinical photograph — strongly recommended; some payers and most malpractice carriers expect it. Note that a photo was captured and stored in the chart.
• Differential diagnosis — the lesions you are trying to rule in or out (e.g., "rule out dysplasia vs. frictional keratosis"). Establishes medical necessity for sending a specimen to a lab.
• Consent / PARQ — procedure, alternatives (including biopsy with histopathology, watchful waiting with photo-documented re-evaluation in 2 weeks, referral to OMFS or oral medicine), risks (bleeding, non-diagnostic specimen, sampling error, need for definitive biopsy), and questions answered. Document signed or verbal consent.
• Anesthesia, if any — most exfoliative cytology requires no anesthesia; if topical or local was used, document agent, concentration, and carpules. Don't auto-populate anesthesia lines you didn't actually deliver.
• Sampling technique — explicitly: "exfoliative cytology specimen obtained by [scrape with #15 blade / cytobrush / swab / spatula] from the lesion surface." This sentence is what differentiates D7287 from D7286/D7288 in the chart.
• Specimen handling — slide(s) prepared, fixative used (95% alcohol spray, alcohol jar, or liquid-based cytology medium per the lab), labeling with patient identifiers, and chain-of-custody. Cytology specimens are not placed in formalin — formalin denatures cytologic stains.
• Pathology lab — receiving lab name, requisition number, and the specific cytologic interpretation requested (e.g., "exfoliative cytology, rule out dysplasia").
• Complications — bleeding, patient tolerance, syncope, vasovagal — or "none."
• Post-op instructions — typically minimal for cytology (no rinsing for 30 minutes if applicable, watch for unexpected bleeding, call with concerns).
• Result-disclosure plan — when and how the patient will be informed of the cytology result, and the contingency if the result is positive, atypical, or non-diagnostic. A "non-diagnostic" or "atypical" cytology almost always requires definitive incisional/excisional biopsy (D7286/D7285), and the chart should anticipate that escalation.
• Next visit / follow-up — concrete date for results review or definitive biopsy referral. A cytology specimen lost to follow-up is the most common audit/malpractice exposure on this code.

The chart-note "amnesia test" is especially important for sampling codes: if a reviewer can't tell from the note whether you brushed the surface (D7287), brushed through the full epithelium (D7288), or removed a piece of tissue (D7286), the carrier will pick the cheapest interpretation, and a plaintiff will pick the most damaging.

Common denial reasons

Common denial, downgrade, and audit triggers for D7287:

• Code-descriptor mismatch in the chart — note describes margins, sutures, formalin, or "lesion excised," but billed as D7287. Reviewer recodes to D7286 (often at a lower allowable than the office expected) or denies for "service not consistent with documented procedure." This is the most common denial pattern post-2023.
• D7287 billed when D7288 was performed — true transepithelial brush biopsies (OralCDx BrushTest) belong to D7288. Carriers that recognize the brand pathway will deny D7287 if the supply log shows a D7288-specific brush kit.
• Billed alongside D7286/D7285 on the same lesion — bundled by most carriers as inclusive; only the definitive biopsy pays. Document separate sites if both are clinically warranted.
• Missing pathology lab destination — note doesn't name the receiving lab or include a requisition number. Carriers and auditors read this as a sample never sent.
• No clinical photo or measurement — payers that require image documentation for biopsy/cytology codes will deny without it. AAOMS and most malpractice carriers consider a pre-op photo standard of care.
• Default-normal lesion description — copy-paste "white plaque, asymptomatic" with no measurements, borders, or duration on every cytology code looks fabricated.
• Result not reconciled in chart — the cytology was sent but no pathology report is filed, no patient was notified, and no follow-up was scheduled. This is the highest-malpractice-exposure failure mode for this code, and OIG audits in several states have cited "specimen sent without follow-up" as a quality-of-care finding.
• Medicaid non-covered — many state Medicaid plans simply don't cover exfoliative cytology codes; denial is for benefit, not documentation.
• Frequency / repeat sampling — repeat D7287 on the same lesion without escalation to definitive biopsy is denied as not medically necessary in most carrier clinical policies.
• Submitted without diagnosis code (medical cross) — when cross-coding to medical, missing or non-specific ICD-10 (e.g., K13.79 unspecified instead of K13.21 leukoplakia) triggers automated medical denials.

Related templates